Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease
- PMID: 24259947
- PMCID: PMC3821915
- DOI: 10.1155/2013/148526
Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease
Abstract
Background and aims: There is growing evidence that white adipose tissue is an important contributor in the pathogenesis of alcoholic liver disease (ALD). We investigated serum concentrations of total adiponectin (Acrp30), leptin, and resistin in patients with chronic alcohol abuse and different grades of liver dysfunction, as well as ALD complications.
Materials and methods: One hundred forty-seven consecutive inpatients with ALD were prospectively recruited. The evaluation of plasma adipokine levels was performed using immunoenzymatic ELISA tests. Multivariable logistic regression was applied in order to select independent predictors of advanced liver dysfunction and the disease complications.
Results: Acrp30 and resistin levels were significantly higher in patients with ALD than in controls. Lower leptin levels in females with ALD compared to controls, but no significant differences in leptin concentrations in males, were found. High serum Acrp30 level revealed an independent association with advanced liver dysfunction, as well as the development of ALD complications, that is, ascites and hepatic encephalopathy.
Conclusion: Gender-related differences in serum leptin concentrations may influence the ALD course, different in females compared with males. Serum Acrp30 level may serve as a potential prognostic indicator for patients with ALD.
Similar articles
-
The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC).Lung Cancer. 2008 Sep;61(3):391-7. doi: 10.1016/j.lungcan.2008.01.018. Epub 2008 Mar 14. Lung Cancer. 2008. PMID: 18342391
-
Leptin, adiponectin, resistin, visfatin serum levels and idiopathic recurrent pericarditis: biomarkers of disease activity? A preliminary report.Clin Exp Rheumatol. 2013 Mar-Apr;31(2):207-12. Epub 2012 Nov 8. Clin Exp Rheumatol. 2013. PMID: 23137677
-
Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.Adv Med Sci. 2009;54(2):177-82. doi: 10.2478/v10039-009-0047-y. Adv Med Sci. 2009. PMID: 20022856
-
Association of circulating resistin, leptin, adiponectin and visfatin levels with Behçet disease: a meta-analysis.Clin Exp Dermatol. 2018 Jul;43(5):536-545. doi: 10.1111/ced.13383. Epub 2018 Jan 22. Clin Exp Dermatol. 2018. PMID: 29356069 Review.
-
Serum Leptin, Resistin, and Adiponectin Concentrations in Psoriasis: A Meta-Analysis of Observational Studies.Dermatology. 2017;233(5):378-389. doi: 10.1159/000481882. Epub 2017 Dec 13. Dermatology. 2017. PMID: 29232663 Review.
Cited by
-
Ethnopharmacological Applications Targeting Alcohol Abuse: Overview and Outlook.Front Pharmacol. 2020 Feb 14;10:1593. doi: 10.3389/fphar.2019.01593. eCollection 2019. Front Pharmacol. 2020. PMID: 32116660 Free PMC article. Review.
-
Prognostic Significance of the Systemic Inflammatory and Immune Balance in Alcoholic Liver Disease with a Focus on Gender-Related Differences.PLoS One. 2015 Jun 24;10(6):e0128347. doi: 10.1371/journal.pone.0128347. eCollection 2015. PLoS One. 2015. PMID: 26107937 Free PMC article.
-
Clinical Therapeutic Effect of Naloxone Combined with Hemodialysis on Acute Severe Alcoholism.Med Sci Monit. 2018 Aug 2;24:5363-5367. doi: 10.12659/MSM.908382. Med Sci Monit. 2018. PMID: 30068901 Free PMC article.
-
Circulating fibroblast growth factor 21 in patients with liver cirrhosis.Clin Exp Med. 2018 Feb;18(1):63-69. doi: 10.1007/s10238-017-0468-z. Epub 2017 Jul 25. Clin Exp Med. 2018. PMID: 28744589
-
Adipokines in Liver Cirrhosis.Int J Mol Sci. 2017 Jun 29;18(7):1392. doi: 10.3390/ijms18071392. Int J Mol Sci. 2017. PMID: 28661458 Free PMC article. Review.
References
-
- Marra F, Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50(3):957–969. - PubMed
-
- Parola M, Marra F. Adipokines and redox signaling: impact on fatty liver disease. Antioxidants and Redox Signaling. 2011;15(2):461–483. - PubMed
-
- Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine and Growth Factor Reviews. 2007;18(3-4):313–325. - PubMed
-
- Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2008;27(5):412–421. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous